Delirium after interleukin-2 and alpha-interferon therapy for renal cell carcinoma.
A 55-year-old man receiving alpha-interferon and interleukin-2 therapy for renal cell carcinoma presented with seizures and delirium. A CT-scan of the cerebrum did not reveal any disorder. Both alpha-interferon and interleukin-2 were stopped. Treatment with steroids led to complete regression of central nervous system symptomatology. We emphasize the importance of ruling out iatrogenesis in patients treated with alpha-interferon and/or interleukin-2 who display neuropsychiatric symptoms.
van Steijn
J H
JH
Department of Medical Oncology, University Hospital Groningen, The Netherlands. j.h.m.van.steijn@int.azg.nl
Nieboer
P
P
Hospers
G A
GA
de Vries
E G
EG
Mulder
N H
NH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003693:Delirium / Q000139:chemically induced*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged